Kiniksa Pharmaceuticals Ltd (KNSA) — Financial Flexibility Index
Kiniksa Pharmaceuticals Ltd (KNSA) has a Financial Flexibility Index of 0.23x as of March 2026. Free cash flow of $50.36 Million (operating CF $50.20 Million minus capex $161.00K) represents 0% of total liabilities ($219.59 Million). Check KNSA capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Kiniksa Pharmaceuticals Ltd Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Kiniksa Pharmaceuticals Ltd across 10 annual periods. See working capital position of Kiniksa Pharmaceuticals Ltd to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Kiniksa Pharmaceuticals Ltd (2016–2025)
Year-by-year free cash flow to debt coverage for Kiniksa Pharmaceuticals Ltd. For the full company profile including market capitalisation, see Kiniksa Pharmaceuticals Ltd (KNSA) market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.13x | $25.97 Million | $25.69 Million | $196.03 Million | ▼ -27.5% |
| 2024 | 0.18x | $25.97 Million | $25.69 Million | $142.12 Million | ▲ +19.0% |
| 2023 | 0.15x | $13.43 Million | $13.30 Million | $87.48 Million | ▲ +65.0% |
| 2022 | 0.09x | $5.91 Million | $5.81 Million | $63.52 Million | ▲ +104.2% |
| 2021 | -2.22x | $-105.88 Million | $-126.30 Million | $47.76 Million | ▲ +38.9% |
| 2020 | -3.63x | $-136.25 Million | $-136.53 Million | $37.53 Million | ▲ +31.9% |
| 2019 | -5.33x | $-155.17 Million | $-158.37 Million | $29.11 Million | ▼ -200.6% |
| 2018 | -1.77x | $-75.72 Million | $-81.01 Million | $42.70 Million | ▼ -385.2% |
| 2017 | -0.37x | $-50.15 Million | $-50.22 Million | $137.20 Million | ▼ -37.4% |
| 2016 | -0.27x | $-21.86 Million | $-21.87 Million | $82.20 Million | — |